Kayne Anderson Rudnick Investment Management LLC Lowers Position in Zoetis Inc. $ZTS

Key Points

• Kayne Anderson Rudnick Investment Management LLC reduced its stake in Zoetis Inc. by 3.8%, holding 555,656 shares after selling 21,974 shares in the first quarter.
• Several institutional investors have increased their positions in Zoetis recently, with Brighton Jones LLC boosting its stake by 180.4%.
• Wall Street analysts have a mixed outlook on Zoetis, with four rating it as a "Buy" and four as a "Hold", while price targets vary significantly from $155 to $215.

Kayne Anderson Rudnick Investment Management LLC lessened its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 3.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 555,656 shares of the company's stock after selling 21,974 shares during the quarter. Kayne Anderson Rudnick Investment Management LLC owned 0.12% of Zoetis worth $91,489,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of the business. Brighton Jones LLC grew its stake in shares of Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock worth $754,000 after acquiring an additional 2,978 shares during the period. XTX Topco Ltd purchased a new stake in shares of Zoetis in the 4th quarter valued at about $216,000. First Trust Advisors LP raised its holdings in shares of Zoetis by 134.8% in the 4th quarter. First Trust Advisors LP now owns 104,496 shares of the company's stock valued at $17,026,000 after acquiring an additional 59,990 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in shares of Zoetis by 11.0% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,627 shares of the company's stock valued at $591,000 after buying an additional 358 shares in the last quarter. Finally, Coppell Advisory Solutions LLC raised its holdings in shares of Zoetis by 18.0% during the 4th quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock valued at $68,000 after buying an additional 64 shares in the last quarter. Institutional investors own 92.80% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ZTS. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and decreased their price objective for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and cut their price objective for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Piper Sandler lifted their price target on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research report on Monday, August 11th. Finally, UBS Group lowered their price objective on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $202.43.

Zoetis Stock Performance

Shares of ZTS opened at $156.3180 on Friday. The business has a fifty day moving average of $153.84 and a 200 day moving average of $158.52. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The firm has a market capitalization of $69.28 billion, a P/E ratio of 26.91, a PEG ratio of 2.51 and a beta of 0.88.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. During the same quarter in the previous year, the company posted $1.56 earnings per share. Zoetis's revenue for the quarter was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 652 shares of the company's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the transaction, the executive vice president owned 15,129 shares of the company's stock, valued at $2,571,930. This represents a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.18% of the stock is currently owned by company insiders.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.